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Abstract
Background: Approximately 210 million people are estimated to have chronic obstructive pulmonary disease
[COPD] worldwide. The burden of disease is known to be high, though less is known about those of a younger
age. The aim of this study was to investigate the wider personal, economic and societal burden of COPD on a
cross country working-age cohort.
Methods: A cross-country [Brazil, China, Germany, Turkey, US, UK] cross-sectional survey methodology was utilised
to answer the research questions. 2426 participants aged 45-67 recruited via a number of recruitment methods
specific to each country completed the full survey. Inclusion criteria were a recalled physician diagnosis of COPD, a
smoking history of > 10 pack years and the use of COPD medications in the previous 3 months prior to
questioning. The survey included items from the validated Work Productivity and Activity Impairment [WPAI] scale
and the EuroQoL 5 Dimension [EQ-5D] scale. Disease severity was measured using the 5-point MRC [Medical
Research Council] dyspnoea scale as a surrogate measure.
Results: 64% had either moderate [n = 1012] or severe [n = 521] COPD, although this varied by country. 75% of
the cohort reported at least one comorbid condition. Quality of life declined with severity of illness [mild, mean
EQ-5D score = 0.84; moderate 0.58; severe 0.41]. The annual cost of healthcare utilisation [excluding treatment
costs and diagnostic tests] per individual was estimated to be $2,364 [£1,500]. For those remaining in active
employment [n: 677]: lost time from work cost the individual an average of $880 [£556] per annum and lifetime
losses of $7,365 [£4,661] amounting to $596,000 [£377,000] for the cohort. 447 [~40%] of the working population
had retired prematurely because of COPD incurring individual estimated lifetime income losses of $316,000
[£200,000] or a combined total of $141 m [£89.6 m]. As the mean age of retirees was 58.3 and average time since
retirement was 4 years, this suggests the average age of retirement is around 54. This would mean a high societal
and economic impact in all study countries, particularly where typical state retirement ages are higher, for example
in Brazil, Germany and the UK [65] and the US [65,66,67], compared to Turkey [58 for women, 60 for men] and
China [60].
Conclusions: Although generalisation across a broader COPD population is limited due to the varied participant
recruitment methods, these data nevertheless suggest that COPD has significant personal, economic and societal
burden on working age people. Further efforts to improve COPD diagnosis and management are required.
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Background
Chronic Obstructive Pulmonary Disease [COPD] is one of
the world’s most common non-communicable health pro-
blems [1]. Approximately 210 million people are known to
have the condition [2], although the true prevalence may
well be higher due to under-diagnosis [3]. By 2020, COPD
is predicted to become the third leading cause of death
worldwide [4]. Prevalence is increasing both in developing
and developed countries as a result of worldwide tobacco
consumption [5,6], environmental exposures such as bio-
mass fuel smoke [7] and the growing elderly population
[8]. It is recognised that comorbid diseases commonly
occur with COPD [9-11]. Although COPD is considered
to be a disease of later years, estimates suggest that 50% of
those with COPD are less than 65 years old [12,13], many
of whom are likely to be in paid employment.
Although there is a wealth of epidemiological data on
the global impact of COPD, data on its economic impact
are limited, particularly in terms of how the condition
directly affects younger sufferers’ ability to work and main-
tain active productive lives. The World Health Organisa-
tion [WHO] has estimated that globally COPD results in
an annual loss of productivity of 27,700 years [measured
by disability adjusted life years [DALYs] [14]. This estima-
tion places COPD eleventh as a worldwide cause of disease
burden; by 2030 [15] it is predicted to be seventh highest.
It is important that we understand the true costs of
chronic diseases such as COPD to inform healthcare
policy and to target resources effectively [16]. Several
studies in the US, UK and Europe have attempted to
highlight the financial burden of COPD by estimating
the direct costs of health care utilization [17,18] or lost
productivity [19,20]. However, direct costs only account
for a proportion of cost, and studies to date have not
captured the full extent of the economic burden in
terms of impact on younger individuals, their families
and society as a whole.
Objectives
This cross-country cross-sectional survey aimed to
expand current understanding of the impact of COPD
and to demonstrate its wider potential costs in a working
age population. It was designed as a hypothesis-generat-
ing exercise to identify the factors likely to influence the
economic burden of the disease, which can be the subject
of further research. Here we describe the observed effects
of COPD on: income, employment, work productivity,
healthcare utilization and quality of life.
Methods
Study design and respondents
The cross-sectional survey was conducted between July
and September 2009 in Brazil, China, Germany, Turkey,
UK and US. A contract research organisation [CRO]
identified, recruited and interviewed respondents follow-
ing a protocol.
The aim was to recruit a broad mix of respondents;
representing wide demographics [including working sta-
tus] and with a range of disease severity. A mixed meth-
ods approach to recruitment was therefore used
dependent on country-specific factors. These recruit-
ment methods are described in Table 1.
Inclusion Criteria
Respondents were eligible if they were 45-67 years,
reported a physician diagnosis of COPD, Chronic
Obstructive Airways Disease [COAD], Chronic Obstruc-
tive Lung Disease [COLD], emphysema, chronic bron-
chitis or alpha 1-antitrypsin deficiency [A1AD], and had
been prescribed respiratory medication during the pre-
ceding three months. With the exception of those with
A1AD, respondents had to be current or ex-smokers
with a minimal history of ten pack years. Smoking his-
tory was used to enhance the accuracy of identification
of those with COPD, as in Western countries 80-90% of
people with COPD are likely to be current or past smo-
kers [18]. In developing countries, environmental factors
play a significant role in the aetiology of the disease
[7,21]. As a result, respondents in Brazil and China who
did not have a minimum cigarette pack year history but
otherwise met the inclusion criteria were included if
they were at risk of COPD via biomass exposure. This
risk was defined as having an indoor open fire and
using solid fuel as a primary means of cooking or heat-
ing for more than 6 months across the lifetime.
Questionnaires
Interviews were conducted using a structured survey
incorporating:
• Clinical and demographic data
• Recall of physician-diagnosed comorbidities: adapted
from a pre-determined list of conditions [17]. The list
included the following comorbidities: arthritis, asthma,
cancer or tumour, anxiety, depression, diabetes, cardi-
ovascular disease, hypertension, other lung conditions
[invitation to specify which], and none.
• Disease severity classified as mild [1,2], moderate
[3,4] or severe [5] using the Medical Research Coun-
cil dyspnoea scale modified by Bestall et al [22].
• The amount of health care utilised within the last
month, including GP, outpatient, inpatient utilisa-
tion, emergency hospital services and pulmonary
rehabilitation.
• Quality of life was measured using the validated,
generic, preference-based EuroQoL Group 5
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Dimension [EQ-5D] self-report questionnaire [23],
which has been applied to a wide range of health
conditions. The EQ-5D contains 5 components;
‘mobility’, ‘self-care’, ‘usual activities’, ‘pain/discom-
fort’ and ‘anxiety/depression.’ Each component is
scored as either: ‘no problems’ [level 1], ‘some pro-
blems’ [level 2] or ‘severe problems’ [level 3], defin-
ing the patient’s current health state. Each possible
health state has been valued, from a societal perspec-
tive, on a scale of 1 representing full health and 0 for
dead [range -0.594 to 1 where negative values are
valued as worse than dead] using preference-based
methods by a sample drawn from the general popu-
lation. The self-defined health state of the patient is
thus linked to the social utility value in the two-
stage process. The average values for the respon-
dents were compared to age-adjusted population
values for those countries where normative data
were available [Germany, US and UK] [24].
A further dimension measured ‘health state today’ on
a visual analogue scale [VAS] described to the respon-
dent, where 0 represented ‘worst imaginable state’, 100
being ‘best imaginable state’. The results are then pre-
sented on a 0 to 1 scale, whereby a score of 1 represents
the best health state imaginable and 0 represents a
health state equivalent to being dead. This gives a
patient valuation of the health state [albeit non-prefer-
ence-based] as opposed to the societal value from the
questionnaire and matrix.
Table 1 Recruitment and questioning procedure
Country Recruitment procedure Interview
method
Brazil Random selection from a list obtained
from
Telephone*1 and
COPD patient associations [telephone face-to-face*2
interviews], in front of major hospitals,
and
within a variety of public areas with high
footfall rates, including parks and squares
[face-to-face approach]. The towns and
cities included São Paulo, Rio de Janeiro,
Belo Horizonte, Fortaleza, Porto Alegre,
Curitiba, Vitoria, Recife, and represent
most
regions within the country.
China Shanghai was selected as a metropolitan Face-to-face*3
city. It was divided into 300 regions. 40
regions were randomly selected [the
target
sample size for each region was 10
participants]. The interviewer selected the
starting point using a random method,
usually the crossing point of two major
roads. The interviewer then selected every
fifth property using the right-hand rule
[always turn to the right for the next
potential
respondent]-side of the particular street
Germany Random selection from a list obtained
from
Telephone*1
fieldwork, recruitment agencies and the
database at the CRO, self-help groups,
COPD patient associations
www.lungenemphysem-copd.de,
deustsche-
empysemgruppe.de] and panelists of
online
institutes
Turkey Two representative cities were selected Face-to-face*3
from each of the six geographical regions:
Marmara [Istanbul and Bursa], Aegean
[Izmir and Manisa], Central Anatolia
[Ankara
and Kayseri], Black Sea [Samsun and
Trabzon], Mediterranean [Adana and
Antalya] and Eastern Turkey [Diyarbakir
and
Elazig]. The districts and the streets within
each city were randomly selected. A
stratified random sample of buildings was
used. The interviewers adopted a walking
rule for each street, approaching the
Table 1 Recruitment and questioning procedure
(Continued)
occupant at every fourth property on the
right-hand-side. All work places were also
contacted within each of these buildings.
UK 6-8 participants were recruited from 40 Telephone*1
general practices and 25 pharmacies [at
least one per major town/city] and invited
to
contact the researchers. The British Lung
Foundation regional groups and local
’Breathe Easy’ groups also randomly
selected members.
US Random selection from a known list of Telephone*1
people diagnosed with: COPD obtained
from a market research organization
*1Interviews were conducted at a variety of times between 09:00 and 21:00,
Monday-Sunday.
*2 Interviews were conducted in public places, including parks and outside a
hospital.
*3 Door-to-door interviewing employing the stated sampling criteria.
Fletcher et al. BMC Public Health 2011, 11:612
http://www.biomedcentral.com/1471-2458/11/612
Page 3 of 13
Impact on work in the preceding 7 days was estimated
using the Work Productivity and Activity Impairment
Questionnaire: Specific Health problem V2.0 [WPAI:
SHP] [25]. To assess the overall impact on productivity,
the WPAI generates 4 scores: absenteeism [hours of
work missed due to illness], presenteeism [impact of ill-
ness on productivity while at work], work productivity
loss [combined impact of absenteeism and presenteeism]
and activity impairment [regular activities]. The esti-
mates of reduced work input were valued using average
earnings for each country in the absence of detailed
information on occupational categories. We used the
human capital approach to measure productivity losses
as it includes all productive time lost by those of work-
ing age [26].
The losses to society from premature retirement were
estimated by calculating the average annual earnings for
the number of years of full-time work lost. We used a
pragmatic approach, in the absence of reliable data on
friction periods for all countries. Total productivity
losses were estimated and sensitivity analysis applied to
show the potential reduction in social effect if indeed
absent workers were easily replaced.
Additional indicators of burden were identified during
patient focus groups and used to generate further ques-
tions. These included the economic impact on carers
and family, the care needs of patients, work history,
social activities, healthcare utilisation, daily activities and
future aspirations. Questions were then piloted in face-
to-face interviews with COPD patients and amended as
necessary. The final survey was piloted in the UK by tel-
ephone and in China using door-to-door interviewing.
Surveys were translated into the main language of each
country, back translated and revised as needed. Final
survey interviews were conducted in the main language
of each country.
Ethics
Ethical approval was not deemed necessary following
careful consideration by Education for Health internal
governance committee and the international steering
group. The survey took place among the general public
and the data was collected and the dataset generated via
a contract market research company. Participation in
the study was voluntary and data was collected anon-
ymously. Respondents were informed that their opinions
would remain confidential and the data would be col-
lated and presented in an aggregated and anonymous
format. All respondents provided informed consent
prior to participation.
The study was undertaken in accordance with market
research standards and Codes of conduct including ISO
20252 [http://www.mrs.org.uk/standards/other.htm],
Market Research Society Code of Conduct [http://www.
mrs.org.uk/standards/codeconduct.htm], EPHMRA
[http://www.ephmra.org/professional-standards.aspx]
ESOMAR [http://www.esomar.org/]. This binds the
CRO to all applicable laws protecting personal data.
Health economic data
The financial impact of COPD was estimated for each
country as the annual loss of income resulting from
work impairment and projected to lifetime losses using
expected working life data. The sample total was
expressed in US dollars using purchasing power parities
[PPP]. The pound sterling figures were calculated from
a simple exchange rate conversion. [$1 = £0.63].
The underlying assumptions were a retirement age of
65 years, an average hourly wage from national income
statistics and in the absence of long term data, that the
number of working hours lost per week due to COPD
would remain constant over a working lifetime. Due to
the progressive nature of the condition these could be
conservative assumptions as the increasing severity of
the disease is likely to lead to increasing impact on
work productivity before forced retirement. This will
partly be offset by the use of average wage rates when
COPD patients may earn less than the average. The cus-
tomary retirement age [in years] in the study countries
at the time of the study was as follows: Brazil, Germany
and the UK, 65; US, 65-67; China, 60 and Turkey, 58[F]
& 60 [M]. A sensitivity analysis was carried out for
those retiring over 65 years assuming a standard age of
67 years.
Annual income loss was calculated using the following
formula: number of respondents × % with work impair-
ment × average hours lost per week × hourly wage ×
52. The lifetime loss formula: 65 minus actual age of
retirement × annual loss discounted at 3.5% per annum.
Potential loss of income was calculated for carers. In
the absence of detailed information we made the follow-
ing assumptions about carers’ ability to participate in
the workforce: those who provided constant care were
assumed to be out of the paid labour force; carers who
provided care for part of each day were assumed to miss
a full working week; those providing care on 2-3 days;
half a working week; and those providing care on one
day, one fifth of a working week. Illustrative figures are
presented using the UK as a reference point, assuming
an annual average wage of £23,937 [$ = 37,820].
To evaluate the impact of COPD on healthcare costs
the observed rates of healthcare resource use were mul-
tiplied by unit costs in local currencies, which were
available for all countries except Brazil. The aggregate
impact across all countries was expressed in US$ by
applying PPPs to the local totals [27-32] [personal com-
munication for Turkish PPPs]. It was not possible to
cost pulmonary rehabilitation due to the wide variation
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in service provision across the study countries in terms
of the number and content of sessions.
Sample size and data analysis
Based on a previous international survey of COPD
patients [17], we selected a sample size of 400 respon-
dents in each of the study countries.
Descriptive statistics [mean, standard deviation or
standard error and confidence intervals [95%] were used
to report demographic, clinical and epidemiological data
and categorised into three age bands: 45-54, 55-64 and
65-67 years. Individual country data were pooled to
reflect the international burden of the disease. Data
were analysed using STATA v9.
Results
43,069 respondents were initially approached. Whilst
19,007 declined to partake, others did not meet the age;
diagnosis, medication or smoking criteria [see Figure 1].
3022 then fulfilled the full inclusion criteria. 596 sur-
veys were not included due to non-completion, leaving
a total of 2426 in the study.
Clinical and demographic data
A similar number of respondents were recruited in
each country and the pooled dataset represent a broad
mix of ages and disease severity and respondents were
evenly distributed in relation to gender [table 2]. Levels
of disease severity were widely distributed across the
cohort, and there was substantial variation by country
[Figure 2].
Mean EQ-5D score declined with increasing age and
more markedly with increasing severity of disease [see
Table 3]. These comparisons were both highly signifi-
cant using independent t-tests. This pattern was
observed both for the utility scores calculated from the
EQ-5D questions, which reflected the societal perspec-
tive, and the direct patient scores recorded on the VAS
[Table 4].
Compared with age-related population values for the
UK general population, EQ-5D values in the cohort
were lower reflecting poorer quality of life [see Table 3].
Comparison with EQ5D norms from the US and Ger-
many demonstrated a similar relationship [24]. The
mean EQ5D score for the total cohort was significantly
lower for females [p = 0.000].
Comorbidities
1,809 [75%] respondents stated they had ≥1 comorbid
condition [median 2, range 1-8]. The most commonly
reported conditions were hypertension, asthma, arthritis,
anxiety, depression and diabetes. Respondents with mild
COPD reported less comorbidity than those with more
severe disease [Table 5].
As the number of comorbidities increased quality of
life decreased accordingly [mean EQ 5D score 0.807 SD
[0.01] with 0 comorbidities; 0.661 SD [0.009] with 1-2
comorbidities; and 0.418 [0.014] with ≥3 comorbidities].
The average difference in EQ-5D scores between partici-
pants with no comorbidities and those with 1 or 2
comorbidities was 18%, and for those with more than 2,
Figure 1 CONSORT diagram showing recruitment of study
participants. The CONSORT diagram shows the number of people
involved at each stage of the survey recruitment process, according
to the study criteria. Where a particular individual did not fulfil a
particular criterion, they were not included in the study, and where
such instances occurred, this is reflected along the left hand side of
the figure. The right hand side reflects those included at each stage
of the process, including the number of people [n]. The final figure
included the respondents completing the full survey.
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the difference was 48%. Those retiring early due to
COPD had on average 2.5 [mean] comorbidities com-
pared to 1.1 in those still in active employment.
Health care utilisation
Health care utilisation varied by country both by the
type of service and the extent to which it was used
[Figure 3]. The greatest proportion of health utilisa-
tion was in primary care however hospital inpatient
care accounted for 68% of the total costs. Overall
mean monthly cost per individual was $197 [£125],
but this varied by country with China being the lowest
[$6, £4] and UK being highest [$437, £277]. Total
annual costs for the whole sample were estimated to
be $5.74 m [£3.63 m;]. These estimates exclude the
cost of pulmonary rehabilitation; although 12.3% of
respondents had accessed that service in the previous
month. It did not prove possible to attain a definition
of pulmonary rehabilitation which could be applied
consistently both within and between the countries in
the sample.
Use of all types of healthcare resource increased with
disease severity. For example in mild disease 34.3% of
patients attended the GP and 4.5% required hospital in
patient care whilst in those with severe disease the
equivalent figures were 67.4% and 25%.
Work productivity
Seventy per cent of respondents [n: 1690/2400] were not
employed at the time of questioning. Twenty-six per
cent of these respondents [n: 447] reported that they
had given up work because of their COPD. The mean
age of these early retirees was 58.3 years [range 45 - 67],
of which 53% were female [n: 239/447]. Over half [52%]
had moderate disease [n: 231/447], and 40% severe dis-
ease [n: 177/447]. Of those not in work who did not
retire early due to their COPD [n: 1243], 52% were
female and the mean age was 57.8 years.
The majority of those continuing to work were aged
between 45-54 years [n: 447/710]. The WPAI scores
suggest that COPD affected work productivity [Table 6]
and the loss of productivity was more marked with
advancing years. Within the group who were still work-
ing, impairment of regular activities outside of work is
greater than overall work impairment. However, presen-
teeism was more common than absenteeism.
Disease severity also appeared to affect productivity at
work although those with mild disease were less
affected. However, a considerable increase in impair-
ment was observed in those with moderate disease
across all measures. Overall there was a considerable
smaller percentage of people with severe disease still in
active employment [see Table 7].
The average annual financial loss per patient from lost
working hours was $880 [£556], totalling $596,760
[£376,412] for the cohort and the lifetime losses, $7,365
[£4,661]. This ranged considerably by country due to
the differences in lost working hours and the wide varia-
tion in average salaries; with lifetime losses in China cal-
culated at being the lowest at $678 and Turkey the
highest at $20,805 [Table 8].
Table 2 Clinical and demographic data of respondents
Group [%] Sub-group N
[2,426]
Males
Country Brazil 408 [17] 148 [36]
USA 404 [17] 168 [42]
Germany 400 [16] 167 [42]
UK 400 [16] 208 [52]
China 398 [16] 283 [71]
Turkey 416 [17] 206 [49]
Total 2426 1180
[49]
Age 45-54 1029
[42]
55-64 971 [40]
65-67 426 [18]
Working Status n [%] Males
[%]
n = 2400 [%] Working 710 [29] 360 [51]
Not working 1243
[51]
599 [48]
Retired early due to
COPD*
447 [18] 208 [47]
Missing 26 [1]
Severity: [MRC
Dyspnoea
Scale]
Mild [1, 2] 849 [35]
Moderate [3, 4] 1,012
[42]
Severe [5] 521 [22]
Missing data 44 [2]
Ever smoked on
a daily basis
Yes 2311
[95]
No 115 [5]
Currently smoke Yes 1366
[59]
No 1060
[41]
Mean Pack Years 38
Number of
co-morbidities
by number of
respondents
[n = 2,404]
0 595 [25]
1 753 [31]
2 443 [18]
3 265 [11]
> 4 348 [14]
Missing data 22 [1]
*early retirees
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Figure 2 Severity [MRC] level analysed by country. This bar graph presents percentage data for severity analysed by country [severity
measured using the MRC dyspnoea scale]. *percentage of respondents according to severity level as measured using the Medical Research
Council [MRC] dyspnoea scale. There were no respondents in China who reported severe illness.
Table 3 EQ-5D scores presented by sex, severity and age
Males n: 1,178 Females n: 1,243
Mean EQ-5D 0.678 s.e 0.009 0.596 s.e 0.009
MRC scale Mean s.e n [%]
EQ-
5D
EQ-5D by severity Mild: 0.836 0.007 846 [35]
Moderate: 0.579 0.009 1011 [42]
Severe: 0.409 0.015 521 [22]
Missing data 48 [1]
Total 0.636 0.007 2426 [100]
EQ-5D by age: Age
Band Mean EQ-5D s.e. n [%]
Norm
**
45-54 0.686 0.85 [0.010] 1028 [42]
55-64 0.605 0.80 [0.011] 969 [40]
65-68 0.585 0.79* [0.148] 424 [18]
Missing data 5
Estimated from data for 60-69 age group
Based on UK age norms
Table 4 EQ-5D Scores from the Visual Analogue Scale
[VAS] [scale][23]
n EQ-5D VAS [se]
Country Brazil 408 0.623 [0.010]
China 385 0.799 [0.005]
Germany 400 0.597 [0.011]
Turkey 416 0.543 [0.009]
UK 399 0.511 [0.010]
USA 404 0.544 [0.011]
Total [N] 2,412 0.601 [0.004]
Severity Mild 837 0.733 [0.005]
Moderate 1,011 0.561 [0.006]
Severe 521 0.459 [0.009]
Age 45-54 1,024 0.640 [0.006]
55-64 963 0.583 [0.007]
65-74 425 0.549 [0.001]
The EQ-5D scale is scored 0 [worst imaginable state] to 100 [best imaginable
health state] and is presented on a 0 to 1 scale. A lower EQ-5D VAS score
indicates worse quality of life
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For those who retired prematurely due to COPD [n:
447], the average lifetime earnings losses were estimated
to be $316,000 [£200,000] per individual. This equates to
a total lifetime loss for this group of $141 m [£89.6 m].
Twelve percent [n: 84] of those in work had changed
their employment to one which was either part time or
less physically demanding. Twenty-eight percent [n:
201] of respondents in work were concerned that their
condition would affect their career progression. Loss of
income worried those both still in work and those not
working. Forty-four percent [n: 314] of those still
employed expressed concern about the consequences of
COPD on their future earning capacity.37% [n: 896/
2426] of all respondents reported that their total income
had decreased as a consequence of their COPD, of
which 80% [n: 719] indicated that this had a negative
effect on their lifestyle.
Twenty-two percent [n: 534] of the sample required
regular care or help from a family member, friend or
neighbour [as opposed to a professional carer]. Of these,
289 [54%] needed this care either constantly or for part
of every day.
Table 5 Comorbidities according to disease severity
Mild [MRC*** 1-2****] Moderate [MRC 3-4] Severity [MRC 5]
[n = 849] [n = 1012] [n = 521]
Zero comorbidities 44% [376] 15% [152] 14% [71]
[n = 595] [%**]
1-2 comorbidities 46% [391] 53% [533] 49% [255]
[n = 1196]
≥3 comorbidities 10% [82] 32% [327] 37% [195]
[n = 613]
*2382 reported disease severity [44 = missing data from cohort of 2426]
**The percentage with a particular level of disease and number of co-morbidities within each disease level
***= Medical Research Council
****1-2 = mild severity of disease, 3-4 = moderate severity of disease, 5 = severe disease
Figure 3 Healthcare utilisation analysed by country. The graphical representation here illustrates healthcare utilisation by utility type, and is
presented based on a within-country analysis. *percentage of respondents utilising a healthcare resource within the last month. Respondents
reported all utilities used within the last month.
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The potential annual loss of income to carers was
calculated as being $16,045 [£10,155]. However, if
data are used only for carers of respondents who
answered positively to the question ‘has your need
for care had an impact on the work activities of your
carer’ [39% n: 54] the annual loss amounted to less at
$6,431[£4,070].
Discussion
The aim of this study was to measure the personal, eco-
nomic and societal impact of COPD on an international
younger, working aged population. The results in each
country suggested a high level of impact of COPD in
terms of personal quality of life, patient and carer com-
mitments to work and utilisation of health care
resources. Data varied between countries but many con-
sistent patterns emerge overall.
The economic impact was revealed by the high per-
centage of people who had been forced to stop working
due to their COPD [~40% n: 447/1157]. This supports
the existing literature which has shown that approxi-
mately one in five people are likely to retire prematurely
due to their COPD [20,33,34]. We conducted a sensitiv-
ity analysis which assumed a standard retirement age of
67 [rather than 65]; this raised the estimate of produc-
tivity loss from early retirement due to COPD to over
$160 m [£101 m]. If, as has been proposed in many
countries, retirement age is raised [35], the costs from
premature retirement will rise.
Of those reporting to have retired early due to their
COPD, 40% [n: 177/447] had severe disease compared
to 9% [n: 62/710] with severe disease who remained in
work. Disease severity at the point of retirement was
unknown, however, 64% [n: 284] of retirees had retired
at least 4 years before the study so their disease severity
may have worsened. It is therefore not possible to state
conclusively that disease severity is the main cause of
early retirement. The ability to remain in work may well
be dependent on other factors such as the type of
employment and the flexibility of the employer, as some
people with moderate disease do continue to remain
actively employed [32%, n: 226/710] and yet many do
not [52%, n: 231/447]. This would be worthy of further
Table 6 Productivity [WPAI] and age
Age
range
45-54
years
55-64
years
65-67
years
WPAI Total
% mean
[CI]
% mean
[CI]
% mean
[CI]
n n n n
Absenteeism 3.2% 6.5% 10.7% 4.7%
[% who missed work
due
[2.0, 4.4] [3.8, 9.3] [0.3, 21.0] [3.4, 5.9]
to COPD in the last
week]
n = 411 n = 216 n = 32 n = 659
Presenteeism 8.8% 11.7% 14.9% 10.0%
[% who were affected
in
[6.9, 10.7] [8.4, 15.1] [6.4, 23.3] [8.4, 11.7]
the last week due to
their
n = 447 n = 230 n = 33 n = 710
COPD]
Regular activities 10.7% 15.4% 28.5% 13.0%
[% who were affected [8.5, 12.9] [11.7, 19.2] [18.2, 38.8] [11.1,
15.0 ]
within the last week
due
n = 447 n = 230 n = 33 n = 710
their COPD]
Table 7 Productivity [WPAI] and severity level
Severity
WPAI Mild Moderate Severe Total
% mean
[CI]
%mean
[CI]
% mean
[CI]
% mean
[CI]
n n n n
Absenteeism 2.2% 8.3% 7.6% 4.6%
[% who missed work
due
[1.2, 3.2] [5.2, 11.5] [2.1, 13.0] [3.3, 5.9]
to COPD in the last
week]
n = 383 n = 205 n = 54 n = 642
Presenteeism 5.2% 16.8% 18.9% 10%
[% who were affected
in
[3.7, 6.7] [12.6, 19.6] [10.4, 27.3] [8.3, 11.7]
the last week due to
their
n = 405 n = 226 n = 62 n = 693
COPD]
Regular activities 5.9% 20.7% 32.3% 13.1%
[% who were affected [4.1, 7.7] [16.9, 24.4] [22.8, 41.7] [11.2,
15.0]
within the last week
due
n = 405 n = 226 n = 62 n = 693
their COPD]
Table 8 Financial loss from reduced working hours
Country N Annual average loss Lifetime average losses
*[$] [se] **[$] [se]
Brazil 151 827[235] 5849 [1572]
China 215 77 [24] 678 [182]
Germany 161 923 [368] 8099 [3181]
Turkey 55 2,014 [585] 20,805 [6486]
UK 64 2,176 [924] 18,153 [8690]
USA 31 1,805 [1,223] 11,205 [8459]
Total Weighted 677 880 7,365
average***
*Average working hours lost × local average wage × $ppp
**Sum of annual income loss each year up to statutory retirement age
discounted to present value at 3.5% per annum
*** Weighted average across whole sub-sample of 677 with work loss.
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research and may help to find some of the solutions to
keeping people with COPD in active work for longer.
There are several reasons, apart from their COPD, for
a large number of the survey population not being in
work [n: 1243] although still of working age. In this
group there are likely to be people who had; actively
decided not to work, already retired, were unemployed
and those who had retired early for another personal or
health reason. The ability to remain in active employ-
ment with COPD was an issue for all respondents from
every country, who had reported concerns about their
future earning capacity. As a result, they felt unable to
maintain their previous lifestyles and had difficulty plan-
ning ahead in terms of financial commitments. Other
respondents reported continuing to work despite their
COPD, although it was noticeable that those with more
severe disease were less likely to remain in employment.
Those with moderate and severe disease were more
severely affected in terms of productivity than those
with mild disease. There were some inter-country differ-
ences, perhaps explained by differences in welfare and
benefits systems. The absence of any or limited paid
sick leave may pressurise individuals to decide between
caring for their deteriorating health or potentially losing
jobs and income. Therefore, the costs of presenteeism
may extend beyond lost productivity, should COPD
patients decide to continue working.
The survey was conducted during the summer months
for all countries in the Northern Hemisphere [although
this period was wintertime for Brazil]. COPD exacerba-
tions are more common in the winter months [36], so
there may have been some under reporting of the extent
of the effects of COPD on work productivity and health
care utilisation.
Many respondents reported difficulty maintaining
their activity levels outside of work. The number of
those remaining employed, and levels of presenteeism,
suggest some significant efforts are made in terms of
remaining employed. It is possible that as a result of the
effort to remain in work, respondents were making
sacrifices in terms of their capacity to maintain social
activities. Many family members also reported having to
give up work to care for relatives. As COPD predomi-
nately affects people on lower incomes [37] this poten-
tially has serious consequences for families experiencing
a dual loss of income from patient and carer employ-
ment limitations. When coupled with lack of clarity
about prognosis and anticipated morbidity, patients with
COPD and their families face a future of uncertainty
[38].
In our study, there was considerable variation across
countries in the volume, costs and type of health care
utilisation, reflecting differing health systems and pat-
terns of disease severity. Our findings, however, suggest
that COPD patients are heavy users of health care and
that the costs associated with this are high with an aver-
age healthcare utilisation cost of $2,364 [£1,500] per
annum per capita leading to a total amount for this
cohort of $5.74 m [£3.63 m;] per annum. Other studies
have estimated the direct cost of COPD care to be sig-
nificantly less, around $1234-1823 [£781-1154] per
patient [39]. As in previous studies, the greatest costs
were derived from hospital inpatient care [26,40]; how-
ever in our study far more patients reported having vis-
ited their family practitioner at a substantially lower unit
cost. Whilst it is difficult to draw conclusions between
studies due to differences in measurement, healthcare
utilisation costs are high across all studies. Although
COPD is currently under-diagnosed [3], prevalence is
increasing due to increasing numbers of people exposed
to risk factors, the aging population, and earlier detec-
tion. Hence the total cost of healthcare for COPD is
likely to increase, potentially placing further burden on
primary care and hospital care. Whilst further research
is needed to establish the complete picture in terms of
cost effectiveness, skilled multidisciplinary teams in pri-
mary care may help to reduce COPD hospitalization
rates [41]. A recent survey within UK general practice
however suggested 52% of respondents lacked the
appropriate training to manage people with COPD
effectively [42]. As the majority of COPD care is deliv-
ered within primary care, this highlights the need for
investment in sustained educational interventions that
have been shown to improve the quality of life of people
with long term conditions [43].
The impact of COPD on quality of life observed in
our study has been previously reported using a variety
of both generic and disease specific instruments [44].
Similarly, and in line with previous research [45], health-
related quality of life [HRQOL] measured by EQ-5D was
worse for those with more severe disease and higher
numbers of comorbidities. The extent of comorbidity in
this younger study population was considerable and
would appear to be higher than reported before [48-
52%] [17,34]. From the results of this survey it is not
known the extent to which comorbidity affected the
ability to continue in active employment; however this
would worthy of further investigation. It is recom-
mended that patients with airflow limitation should rou-
tinely undergo comprehensive clinical assessments to
identify co-morbid disease [46]. It would appear this is
particularly important in younger patients, as earlier and
more aggressive interventions may keep individuals in
employment for longer.
Published demographic data suggests that COPD is
currently more prevalent in men [12] There were similar
proportions of women and men in this study. This may
reflect the gender differences in survey response rates in
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general [47]. Our study may also be reflecting the chan-
ging trends in female smoking behaviour, and that
impact on COPD prevalence [48].
It is concerning that almost two thirds of the partici-
pants continued to smoke. As smoking cessation is cur-
rently the only known intervention to alter disease
progression [49]; workplace programmes may be helpful
to those still in employment.
It was not our intention to make country compari-
sons, however the results from China are worthy of note
due to the apparent differences between China and the
other countries in all measured parameters. The Chinese
participants, the majority of whom were male [n: 283,
71%], reported milder disease [as measured by MRC
score], higher quality of life, minimal loss of productivity
and less use of health care services yet the Chinese data
contained the highest number of current smokers [n:
329, 83%] compared to the rest of the cohort 59% [n:
1366]. We can surmise from the size of the cohort and
the chosen methodology that these differences may be
culturally specific rather than a reflection of physical
effects of the disease. The concept of ‘face’ or ‘mianzi’,
whereby the social standing of an individual is in rela-
tion to others, is part of Chinese belief systems. Losing
face is something to be avoided and can give rise to dis-
tress caused by shame. It is possible that our questions
relating to disease severity, comorbidities and work were
influenced by these beliefs, resulting in the apparent dif-
ferences between the Chinese data and the rest of the
cohort.
The main strength of this study is that the large data-
set was collected from similar sized samples of the
population in six countries with differing economic,
social and demographic characteristics thus presenting a
wide international perspective on the disease impact.
However this also gives rise to some of the limitations
as the study population cannot be seen as representative
of any larger domain, and the value of pooled analyses
is limited. The advantage of the approach is that a by-
country analysis identifies those aspects of COPD, and
its impact on patients, which are common to a widely
differing set of countries, and those which are limited to
certain societies. The breadth of the data collected
serves to indicate some of the possible reasons for dif-
ferences in the pattern of the disease and its impact
between countries. Consistency in many qualitative rela-
tionships, for example between COPD severity and qual-
ity of life, can be seen across all countries. Whilst
pooled data analysis is not appropriate, to the extent
that the sub-samples are representative of COPD
patients in each country, estimates of aggregate national
burdens may be made.
One major limitation in this study is the fact that
there were differences in the methods of selection of the
study population, recruitment and data collection across
countries. This may have resulted in the observed differ-
ences in the characteristics of the patients; for example,
patients recruited from local patients’ groups [UK] may
have had more severe disease than those recruited ran-
domly from geographical regions [China, Turkey]. The
significant heterogeneity of disease severity between
countries [data not shown] prevents us from pooling the
data or making cross-country comparisons. However,
these data are still valuable to illustrate the global pic-
ture of the burden of COPD.
Where available we used validated questionnaires to
quantify the burden of COPD in a working age popula-
tion. However, there were some aspects of COPD for
which these questionnaires were not available. This
resulted in the development of a small number of speci-
fic, non-validated questions. These questions, despite
being piloted with COPD patients and revised to mini-
mise ambiguities and errors, may not reflect COPD
morbidity with the same degree of reliability as the vali-
dated questionnaires.
Although we used criterion which would identify par-
ticipants with COPD as accurately as possible, the diag-
nosis and reported severity was not verified by
spirometry. The survey was subjective and retrospective
in nature, relying on patients’ recollection of the impact
of COPD over varying time periods; this may have
resulted in either over or underreporting of its impact
[50]. The method of interview [telephone versus face-to-
face] may also have had an impact on the way the ques-
tions were answered with telephone respondents having
the potential to underplay their symptoms in an attempt
to reduce social desirability bias [51]. Many other differ-
ences observed in this study would reflect the demo-
graphic pattern of disease, occupational contexts,
economic drivers and access and affordability of health
care.
Further prospective studies are required to investigate
the impact of COPD on people in work, the precipitat-
ing factors for early retirement, and identify interven-
tions that may keep people actively employed.
Conclusions
This survey demonstrates that COPD has a marked
effect on the working age population. The cost of illness
is possibly more extensive than has previously been
recognised [5,12].
Significant societal benefits could be achieved if COPD
were diagnosed earlier and managed appropriately as
this may enable individuals to optimise their ability to
remain in active employment. Health professionals
should ensure they have the skills to recognise the con-
siderable burden COPD incurs, and the knowledge to
treat sufferers effectively. This in turn should be
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supported by a commitment to invest in appropriate
and accessible health services, including preventative
health and to develop workplace strategies which enable
people with COPD to remain in active employment for
longer.
While some issues related to the study design may
limit the scope for generalisation to all COPD popula-
tions, we hope the issues raised will increase the focus
of attention of the impact of this condition on the
younger populations.
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